Prague Med. Rep. 2015, 116, 181-192
https://doi.org/10.14712/23362936.2015.57
Ormond’s Disease – IgG4-related Disease
References
1. 2008) Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. Rheumatology 47, 1535–1538.
< , S., Lodermeyer, S., Gaa, J., Heemann, U. (https://doi.org/10.1093/rheumatology/ken291>
2. 1905) Rétention rénale par péri-urétérite. Libération externe de l’uretere. Assoc. Fr. Urol. 9, 511–517.
, J. (
3. 2012) Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann. Rheum. Dis. 71, 311–312.
< , M., Uhl, M., Wiech, T., Kollert, F., Thiel, J., Sass, J. O., Walker, U. A., Peter, H. H., Warnatz, K. (https://doi.org/10.1136/annrheumdis-2011-200148>
4. 2014) Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. Urol. Int. 93, 320–325.
< , A. S., Kamper, L., Kukuk, S., Haage, P., Roth, S. (https://doi.org/10.1159/000357814>
5. 2014) The clinical spectrum of IgG4-related disease. Autoimmun. Rev. 13, 1203–1210.
< , P., Ramos-Casals, M., Bosch, X., Stone, J. H. (https://doi.org/10.1016/j.autrev.2014.08.013>
6. 2011) Abdominal infectious aortitis caused by Streptococcus pneumoniae: a case report and literature review. Ann. Vasc. Surg. 25, 266.e9–266.e16.
< , C., Astudillo, L., Deelchand, A., Moskovitch, G., Sailler, L., Bossavy, J. P., Arlet, P. (https://doi.org/10.1016/j.avsg.2010.07.014>
7. 2012) Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. Clin. Exp. Rheumatol. 30, 776–777.
, M. G., Spaggiari, L., Magnani, L., Pipitone, N., Versari, A., Boiardi, L., Pazzola, G., Pattacini, P., Salvarani, C. (
8. 2007) Idiopathic retroperitoneal fibrosis: Clinicopathologic features and differential diagnostic. Kidney Int. 72, 742–753.
< , D., Maestri, R., Palmisano, A., Bosio, S., Greco, P., Manenti, L., Ferretti, S., Cobelli, R., Moroni, G., Dei Tos, A. P., Buzio, C., Vaglio, A. (https://doi.org/10.1038/sj.ki.5002427>
9. 2012) Retroperitoneal fibrosis during etanercept therapy for rheumatoid arthritis. J. Rheumatol. 40, 1931–1933.
< , M., Mathieu, S., Dubost, J. J., Soubrier, M. (https://doi.org/10.3899/jrheum.130324>
10. 2004) Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 13, 635–638.
< , M., Sulli, A., Capellino, S., Villaggio, B., Montagna, P., Seriolo, B., Straub, R. H. (https://doi.org/10.1191/0961203304lu1094oa>
11. 2010) Riedels thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res. (Hoboken) 62, 1312–1318.
< , M., Khosroshahi, A., Nielsen, G. P., Desphande, V., Stone, J. H. (https://doi.org/10.1002/acr.20215>
12. 2008) Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: a retrospective study. Nephron Clin. Pract. 108(3), c213–c220.
< , A. C., Singh, S., Gunda, S. S., Boustead, G. B., Hanbury, D. C., McNicholas, T. A., Farrington, K. (https://doi.org/10.1159/000119715>
13. 2003) Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res. 63, 8742–8748.
, S., Dabrosin, C. (
14. 1996) Retroperitoneal fibrosis. A true connective tissue disease. Rheum. Dis. Clin. North Am. 22, 23–38.
< , G. S., Allen, N. B. (https://doi.org/10.1016/S0889-857X(05)70260-X>
15. 1996) Laparoscopic diagnosis of malignant retroperitoneal fibrosis. J. Endourol. 10, 535–538.
< , B. R., Russo, P., Conlon, K. C. (https://doi.org/10.1089/end.1996.10.535>
16. 2013) Rethinking Ormond’s disease: “idiopathic” retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore) 92, 82–91.
< , A., Carruthers, M. N., Stone, J. H., Shinagare, S., Sainani, N., Hasserjian, R. P., Deshpande, V. (https://doi.org/10.1097/MD.0b013e318289610f>
<PubMed>
17. 2008) Robotic surgery in urology. New EU Magazine of Medicine 2, 84–93.
, I., Toběrný, M., Černohorský, S. (
18. 2014) Clinicopathologic characteristics of IgG4-related retroperitoneal fibrosis among patients initially diagnosed as having idiopathic retroperitoneal fibrosis. Mod. Rheumatol. 1, 1–5.
, B. S., Koh, Y. W., Hong, S., Kim, Y. J., Kim, Y. G., Lee, C. K., Yoo, B. (
19. 2002) Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in Dupuytren’s affected palmar fascia. J. Surg. Res. 103, 146–152.
< , M. A., Wang, X., Payne, W. G., Ko, F., Robson, M. C. (https://doi.org/10.1006/jsre.2001.6350>
20. 2013) Idiopathic vs. secondary retroperitoneal fibrosis: A clinicopathological study of 12 cases with emphasis to possible relationship to IgG4-related disease. Virchovs Arch. 463, 721–730.
< , J., Podhola, M., Kamaradova, K., Novak, I., Dobes, D., Brodak, M., Hacova, M., Ryska, A. (https://doi.org/10.1007/s00428-013-1480-7>
21. 2012) Rituximab therapy for chronic periaortitis. Ann. Rheum. Dis. 71, 1262–1264.
< , F., Corradi, D., Versari, A., Casali, M., Urban, M. L., Buzio, C., Vaglio, A. (https://doi.org/10.1136/annrheumdis-2011-201166>
22. 2001) Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann. Rheum. Dis. 60, 427–428.
< , A., Trapani, A., Leone, N., Actis, G. C., Rizzetto, M. (https://doi.org/10.1136/ard.60.4.427>
<PubMed>
23. 2001) Estrogen, prolactin, and autoimmunity: actions and interactions. Int. Immunopharmacol. 1(6), 995–1008.
< , R. W. (https://doi.org/10.1016/S1567-5769(01)00045-5>
24. 2006) Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches. Nephrol. Dial. Transplant. 21, 2485–2490.
< , G., Gallelli, B., Banfi, G., Sandri, S., Messa, P., Ponticelli, C. (https://doi.org/10.1093/ndt/gfl228>
25. 1948) Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J. Urol. 59, 1072–1079.
< , J. K. (https://doi.org/10.1016/S0022-5347(17)69482-5>
26. 1990) The spectrum of chronic periaortitis. Histopathology 16, 423–431.
< , D. V. (https://doi.org/10.1111/j.1365-2559.1990.tb01541.x>
27. 2012) Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol. Dial. Transplant. 27, 2819–2825.
< , L. G., Aarnoudse, A. J., Hendriksz, T. R., van Bommel, E. F. (https://doi.org/10.1093/ndt/gfr779>
28. 2011) Aortitis: Imaging spectrum of the infectious and inflammatory conditions of the aorta. Radiographics 31, 435–431.
< , C. S., Ocazionez, D., Suri, R., Vargas, D. (https://doi.org/10.1148/rg.312105069>
29. 2011) Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann. Intern. Med. 154, 31–36.
< , P. J. Jr., Feeley, N., Sozio, S. M. (https://doi.org/10.7326/0003-4819-154-1-201101040-00005>
30. 2013) Imaging vasculitis. Best Pract. Res. Clin. Rheumatol. 27, 107–118.
< , W. A. (https://doi.org/10.1016/j.berh.2013.01.001>
31. 2012) Endovascular treatment of infected aortic aneurysms. Eur. J. Vasc. Endovasc. Surg. 44, 385–394.
< , P., Spacek, M., El Samman, K., Belohlavek, O., Mach, T., Jindrak, V., Rohn, V., Stadler, P. (https://doi.org/10.1016/j.ejvs.2012.07.011>
32. 2001) Retroperitoneal fibrosis: a rare complication of Pott’s disease. J. Urol. 166, 622–623.
< , A., Ansari, M. S., Trikha, V., Mittal, R. (https://doi.org/10.1016/S0022-5347(05)66007-7>
33. 2008) Idiopathic retroperitoneal fibrosis: a role for mycophenolate mofetil. Clin. Nephrol. 69, 260–268.
< , R. D., Lake, A. M., Roberts, W. W., Faerber, G. J., Wolf, J. S. Jr. (https://doi.org/10.5414/CNP69260>
34. 2010) The birthday of a new syndrome: IgG4 related diseases constitute a clinical entity. Autoimmun. Rev. 9, 591–594.
< , H., Yamamoto, M., Suzuki, C., Naishiro, Y., Shinomura, Y., Imai, K. (https://doi.org/10.1016/j.autrev.2010.05.003>
35. 2005) Chronic periaortitis: a spectrum of diseases. Curr. Opin. Rheumatol. 17, 34–40.
< , A., Buzio, C. (https://doi.org/10.1097/01.bor.0000145517.83972.40>
36. 2003) Evidence of autoimunity in chronic periaortitis: a prospective study. Am. J. Med. 114, 454–462.
< , A., Corradi, D., Manenti, L., Ferretti, S., Garini, G., Buzio, C. (https://doi.org/10.1016/S0002-9343(03)00056-1>
37. 2006) Retroperitoneal fibrosis. Lancet 367, 241–251.
< , A., Salvarani, C., Buzio, C. (https://doi.org/10.1016/S0140-6736(06)68035-5>
38. 2013) Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum. 65, 2469–2475.
< , A., Catanoso, M. G., Spaggiari, L., Magnani, L., Pipitone, N., Macchioni, P., Pulsatelli, L., Nicastro, M., Becchi, G., Corradi, D., Versari, A., Boiardi, L., Salvarani, C. (https://doi.org/10.1002/art.38032>
39. 2007) Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am. J. Kidney Dis. 49, 615–625.
< , E. F., Siemes, C., Hak, L. E., van der Veer, S. J., Hendriksz, T. R. (https://doi.org/10.1053/j.ajkd.2007.02.268>
40. 2009) Idiopathic retroperitoneal fibrosis: Prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 88, 193–201.
< , E. F., Jansen, I., Hendriksz, T. R., Aarnoudse, A. L. (https://doi.org/10.1097/MD.0b013e3181afc420>
41. 2013) Long-term safety and efficacy of a tamoxifen – Based treatment strategy for idiopathic retroperitoneal fibrosis. Eur. J. Intern. Med. 24, 444–450.
< , E. F., Pelkmans, L. G., van Damme, H., Hendriksz, T. R. (https://doi.org/10.1016/j.ejim.2012.11.010>
42. 2005) Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann. Rheum. Dis. 64, 828–833.
< , K., Keskin, A. G., Uhl, M., Scholz, C., Katzenwadel, A., Vaith, P., Peter, H. H., Walker, U. A. (https://doi.org/10.1136/ard.2004.029793>
<PubMed>
43. 2009) Retroperitoneal fibrosis: A clinicopathologic study with respect to immunoglobulin G4. Am. J. Surg. Pathol. 33, 1833–1839.
< , Y., Onodera, M., Inoue, D., Kitao, A., Matsui, O., Nohara, T., Namikim, M., Kasashima, S., Kawashima, A., Matsumoto, Y., Katayanagi, K., Murata, T., Ishizawa, S., Hosaka, N., Kuriki, K., Nakanuma, Y. (https://doi.org/10.1097/PAS.0b013e3181b72882>
44. 2012) Retroperitoneal and aortic manifestations of immunoglobulin G4-related disease. Semin. Diagn. Pathol. 29, 212–218.
< , Y., Kasashima, S., Inoue, D. (https://doi.org/10.1053/j.semdp.2012.07.003>